Endocan as a prognostic biomarker of triple-negative breast cancer-Reference-Cited by-同舟云学术

Endocan as a prognostic biomarker of triple-negative breast cancer

Published:2016-11-25 Issue:2 Volume:161 Page:269-278
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Sagara Atsunobu,Igarashi Katsuhide,Otsuka Maky,Kodama Akihiro,Yamashita Mutsumi,Sugiura Rei,Karasawa Takeshi,Arakawa Kazuhiko,Narita Michiko,Kuzumaki Naoko,Narita Minoru,Kato Yoshinori^ORCID

Funder

the MEXT-Supported Program for the Strategic Research Foundation at Private Universities

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-016-4057-8.pdf

Reference35 articles.

1. Brenner DR, Brockton NT, Kotsopoulos J, Cotterchio M, Boucher BA, Courneya KS, Knight JA, Olivotto IA, Quan ML, Friedenreich CM (2016) Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes Control 27:459–472. doi: 10.1007/s10552-016-0726-5

2. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728. doi: 10.1002/cncr.22618

3. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O’Regan RM, Gabram SG, Eley JW (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113:357–370. doi: 10.1007/s10549-008-9926-3

4. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20:1071–1082. doi: 10.1007/s10552-009-9331-1

5. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. doi: 10.3322/caac.21332

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1;Journal of Translational Medicine;2024-01-11

2. ANGPTL4 accelerates carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1;2023-05-16

3. Mathematical modeling of tumor growth and treatment: Triple negative breast cancer;Mathematics and Computers in Simulation;2023-02

4. Analysing the effect of trastuzumab treatment on breast cancer stages and cardiac function: A mathematical modeling and numerical simulation;Communications in Mathematical Biology and Neuroscience;2023

5. Clinical significance of blood endocan level in breast cancer patients;The Showa University Journal of Medical Sciences;2023